Loading clinical trials...
Loading clinical trials...
A Phase 1B/2 Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (RICOLINOSTAT) in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
Conditions
Interventions
ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
Locations
2
United States
Local Institution - 201
Boston, Massachusetts, United States
Cleveland Clinic
Cleveland, Ohio, United States
Start Date
March 1, 2014
Primary Completion Date
February 29, 2024
Completion Date
February 29, 2024
Last Updated
March 4, 2025
NCT07249528
NCT06215118
NCT06679101
NCT05969860
NCT06057402
NCT06383143
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions